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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the world’s leading causes of death among cancer patients.
It is important to find a new biomarker that diagnoses HCC and monitors its treatment. In our previous work, we
screened a single-chain antibody (scFv) N14, which could specifically recognize human HepG2 HCC cells but not
human non-cancerous liver LO2 cells. However, the antigen it recognized in the cells remained unknown.
Methods: Recombinant scFv N14 antibody was expressed as an active antibody. Using this antibody with a
combination of immunological and proteomic approaches, we identified the antigen of scFv N14 antibody as the
heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1). The expression of hnRNP A2/B1 in HCC cells was
then investigated by semi-quantitative RT-PCR and immunohistochemistry.
Results: We found that the up-regulation of hnRNP A2/B1 was measured at both transcriptional and translational
levels in rat HCC cells but not in rat hepatic cells. We also found that in various human hepatic tissues, hnRNP A2/
B1 was highly expressed in both human hepatitis virus positive liver tissues and human HCC tissues but not in
normal liver tissues. Interestingly, we observed that the localization of hnRNP A2/B1 in HCC cells was altered during
the development of HCC. In human hepatitis virus infected tissues hnRNP A2/B1 resides exclusively in the nuclei of
hepatocytes. However, when the HCC progressed from a well differentiated to a poorly differentiated stage, hnRNP
A2/B1 was increasingly localized in the cytoplasm. In contrast, the HCC tissues with hnRNP A2/B1 highly expressed
in the nucleus decreased.
Conclusions: This work is the first to show that hnRNP A2/B1 is the antigen specifically recognized by the scFv
N14 antibody in HCC cells. The over-expression of hnRNP A2/B1 was confirmed in cultured human and rat HCC
cell lines, human virus related hepatitis liver tissues and human HCC tissues. The increased localization of hnRNP
A2/B1 in the cytoplasm of HCC cells was revealed during the dedifferentiation of hepatocellular carcinoma.
Therefore, we suggest that the increased expression and cytoplasmic localization of hnRNP A2/B1 can be used as a
diagnostic biomarker to assess the risk of human liver cancer.
Background
Hepatocellular carcinoma (HCC) is one of the world’s
most common types of cancer, and an estimated
500,000 to 1,000,000 patients die of HCC each year [1].
HCC diagnosis is a multistage process, which include
clinical, laboratory, imaging and pathological examina-
tions. Current HCC diagnostic approaches have their
limitation. Histopathological examination is considered
as the most reliable diagnosis of HCC, but a combina-
tion of pathological techniques will certainly improve
diagnostic performance [2]. Furthermore, accurate pre-
diction of the invasive potential of HCC is very impor-
tant for the HCC risk stratification and treatment
monitoring [3].
We have been working with screening human HCC
cell specific antibodies in order to deliver some efficient
biomarkers for the prevention, diagnosis and treatment
of HCC. We previously constructed a single-chain anti-
body library to obtain some hepatoma cell-specific anti-
bodies [4]. We immunized BALB/c mice with HepG2
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VH and VL genes were amplified from the total RNA
and cloned into phagemids (pCANTAB5E). The recom-
binant phagemids were transformed to E. coli TG1 to
construct a mouse phage display library containing
1.1 × 10
6 different clones. This library was screened
with HepG2 cells, which led to the isolation of a
hepatoma cell-specific antibody from a single-chain Fv
antibody library termed N14 (scFv N14). However, the
specific antigen for this scFv antibody was unknown.
In this study, we report the identification of hnRNP
A2/B1 as the antigen recognized by the scFv N14 anti-
body. A literature search showed that hnRNP A2/B1 is a
nuclear RNA-binding protein involved in the splicing of
mRNA and its subsequent transport from the nucleus to
the cytoplasm [5,6]. hnRNP A2 and hnRNP B1 are pro-
duced by alternative splicing of a single-copy gene, and
differ from each other only by an additional 12-amino
acid insertion at the N-terminus of B1[5,6]. In 1996,
Zhou et al f i r s tr e p o r t e dt h a th n R N PA 2 / B 1w a st h e
principal antigen for the lung cancer-specific monoclo-
nal antibody 703D4 [7]. Later, hnRNP A2/B1 has been
found as the antigen of another antibody MG7 that spe-
cific to human gastrointestinal cancers [8]. hnRNP A2/
B1 has been reported to be over-expressed in several
human cancers, including lung cancer [9,10], colon can-
cer [11], breast cancer [12], pancreatic cancer [13], and
stomach cancer [14].
hnRNP A2/B1 is known as a nuclear RNA-binding
protein, but there is an uncertainty of the mis-location
of hnRNP A2/B1 in various cells. Different subcellular
localizations of hnRNP A2/B1 have been reported in
various cases. In cultured cancerous cells, actinomycin
D and the methyltransferase inhibitor adenosine dialde-
hyde can induce nucleocytoplasmic shuttling of hnRNP
A2/B1 or hnRNP A2 [15,16]. In human tissues, different
subcellular localizations of hnRNP A2/B1 were also
observed. Man et al reported various subcellular locali-
z a t i o n so fh n R N PA 2 / B 1a m o n ghistologically different
cells in the longitudinal section of a small bronchiole
[17]. In mammalian lung development, hnRNP A2/B1
was present predominantly in the cytoplasm, but was
sometimes also present in the nucleus depending on cell
types [18].
Therefore, after we identified hnRNP A2/B1 as the
antigen recognized by scFv N14 antibody, we further
investigated the expression and subcellular localization
of hnRNP A2/B1 in the tumor-derived hepatic cell lines
and various human liver tissues samples.
Methods
Cell lines and tissue samples
Human HCC cell line HepG2 (ATCC code, HB-8065),
QGY-7701 (Cell Bank No. TCHu42), QGY-7703 (Cell
B a n kN o .T C H u 4 3 ) ,S M M C - 7 7 2 1( C e l lB a n kN o .
TCHu52), human non-cancerous liver cell line LO2, rat
HCC cell lines CBRH-7919 (Cell Bank No. TCR 2) and
RH-35 (Cell Bank No. TCR 4) were obtained from the
Chinese Academy of Science, Shanghai Cell Library.
Specimens from both normal and diseased liver tissues
were obtained from the Department of Pathology, No.
302 Hospital, China. The study was performed in accor-
dance with the Helsinki declaration, and informed writ-
ten consent was obtained from all patients before
surgery or liver biopsy. 6 normal human liver samples
were both HBsAg and HCVAb negative. In 10 human
hepatitis samples, nine were positive for HBsAg with
only one was positive for HCVAb. 54 human HCC tis-
sue samples were all positive for HBsAg. The clinical
data of the human hepatitis and HCC samples was
shown in Table S1 of the additional file 1. All tissue
samples were collected, fixed in formalin and embedded
in paraffin. Histological differentiation grades for HCC
were determined using the Edmondson and Steiner
s c a l e[ 1 9 ] .T h e5 4H C Cs a m p l e sw e r ec a t e g o r i z e da s
well-differentiated (12 cases, Edmondson grade I), mod-
erately-differentiated (27 cases, Edmondson grade I-II
and II) or poorly-differentiated (15 cases, Edmondson
grade II-III and III). Each sample was reviewed by at
least two pathologists specializing in hepatology.
Isolation rat hepatocytes
Rat hepatocytes were isolated from the livers of female
Wistar rats (200~240 g) using collagenase perfusion.
After anesthetizing the mice with sodium pentobarbital
(100 mg/kg), the liver was first perfused via the portal
vein with Ca
2+-free Krebs-Henseleit (K-H) buffer, then
cut into small pieces and digested with collagenase for
30 min at 37°C. The resulting suspension was filtered
through 200 mesh sieves, centrifuged at 40 × g for 5
min and washed with PBS buffer. Approximately 2 ×
10
8 hepatocytes were obtained and used in the following
experiments. All procedures using animals were con-
ducted in accordance with protocols approved by the
Ethics Committee of the Beijing Institute of Radiation
Medicine.
Expression of scFv N14 antibody in E. coli
DNA encoding the full length of scFv N14 antibody
(719 bp) was amplified by PCR from the phagemid of
scFv N14 using the primers (scFvN14-F: CCGGAATT-
CATGGCCCAGGTCCAGCTGCAG and scFvN14-R:
CCGCTCGAGCCGTTTTATCTCCAAC). The PCR
products with EcoRI and XhoI restricted sites intro-
duced in the primers at the 5′ and 3′ ends were digested
and cloned into the expression vector of pET 24a(+)
(Novagen). The recombinant scFv N14 antibody con-
taining a his6-affinity purification tag was then expressed
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isopropyl b-D-thiogalactoside (IPTG) and incubating for
4 h at 18°C. The cultures were harvested by centrifuga-
tion and the cell pellets were stored at -80°C.
Purification and refolding of recombinant scFv N14
antibody
The cell pellets were resuspended in 15 ml binding buffer
(20 mM Tris-HCl pH 8.0, 5 mM EDTA and 5 mM DTT).
Cells were sonicated on ice and centrifuged at 6,000 rpm
for 10 min at 4°C. The recombinant scFv N14 antibody
was expressed in inclusion bodies. Therefore, inclusion
bodies in the pellets were first washed three times with
washing buffer (20 mM Tris-HCl, pH 8.0, 2 M urea,
5m ME D T Aa n d5m MD T T ) ,t h e nr e s u s p e n d e di n2 0
ml solubilization buffer (20 mM Tris-HCl, pH 8.0, 8 M
urea, 5 mM EDTA and 5 mM DTT), then vortexed until
the pellets dissolved. The refolding of the bound protein
was performed by adding the inclusion bodies to a buffer
containing a low concentration of urea (20 mM Tris-HCl,
pH 8.0, 1 M urea, 5 mM EDTA and 5 mM DTT) until the
final concentration of urea was 2 M. This soluble refolding
fraction was incubated at 4°C for 2 days. The cleared lysate
was then applied to a Ni
2+ NTA-agarose matrix (Qiagen)
column equilibrated with binding buffer (20 mM Tris-HCl
pH 8.0, 5 mM EDTA and 5 mM DTT). The column was
washed using the binding buffer to remove all of the
unbound proteins. Then the bound proteins were eluted
with a linear gradient of 0-200 mM imidazole. Fractions
containing the scFv N14 antibody were collected, concen-
trated to 20 mg/ml and stored at -80°C.
Enzyme-linked immunosorbent assay of recombinant scFv
N14 antibody
The enzyme-linked immunosorbent assay (ELISA) was
used to assess the activity of the recombinant scFv N14
antibody. HepG2 cells and LO2 cells were grown in 96-
well plates and fixed with 4% formaldehyde in PBS buf-
fer for 15 min. Cells were blocked with 5% Casien in
PBS buffer, and cells were then incubated with recombi-
nant scFv N14 antibody (5 μg / m l )a tR Tf o r2h .T h e
secondary antibody used was mouse anti-His6 antibody
(1:3000, Amersham Bioscience). The cells were then
incubated with HRP-conjugated goat anti-mouse IgG
(1:3000, Jackson ImmunoResearch) and 3,3′,5,5′-tetra-
methylbenzydine (Sigma) was used as the substrate for
HRP. The data was measured at 450 nm with a BioRad
microplate reader. PBS buffer rather than the recombi-
nant scFv N14 antibody was used in the negative control
for both HepG2 cells and LO2 cells.
Preparation of nuclear or whole cell protein extracts
Nuclear and cytoplasmic proteins were extracted from
HepG2 cells using the NE-PER® nuclear and cytoplasmic
extraction kit (PIERCE) according to the protocol pro-
vided by the manufacturer. For the whole cell extracts,
cells were lysed in RIPA extraction buffer (150 mM
sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethy-
lenediaminetetraacetic acid, 1 mM PMSF, 1% Triton X-
100, 1% sodium deoxycholate, 0.1% SDS, 5 mg/ml apro-
tinin and 5 mg/ml leupeptin) and were then centrifuged.
T h es u p e r n a t a n tw a su s e da st h ew h o l ec e l lp r o t e i n
extract.
SDS-PAGE, 2-D electrophoresis and Q-TOF analysis
The HepG2 nuclear protein extract was analyzed by
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE), two dimensional electrophoresis (2-
DE). After electrophoresis the gels were stained with
either Coomassie brilliant blue R-250 or electroblotted
onto a polyvinylidene difluoride (PVDF) membrane for
Western blot analysis.
2-DE and Q-TOF analysis were performed according
to the method of Xiao et al [20]. For 2-DE analysis typi-
cally 100 μl of each sample containing about 100 μgo f
protein was loaded onto an immobilized non-linear pH
gradient (IPG) strip, pH 3-10, 7 cm (Amersham
Bioscience). The isoelectric focusing (IEF) was carried
out with the IPGphor system (Amersham Bioscience) at
room temperature as follows: 6 h at 30 V 6 h at 60 V,
30 min at 500 V, 30 min at 1000 V, 10000 Vh at 5000
V. After IEF, the strips were equilibrated with equilibra-
tion buffer (6 M urea, 50 mM Tris-HCl, pH 8.8, 30%
glycerol, 2% SDS, 1% DTT and a minimal amount of
bromophenol blue) for 15 min. The equilibration buffer
was then replaced with a similar equilibration buffer,
containing 1% iodoacetamine instead of DTT, for
another 15 min. The second dimentional electrophoresis
was performed at room temperature on a BioRad system
using a 12% acrylamide gel at a constant current of 80 V
for 15 min, then at 200 V for 45 min. After electrophor-
esis, the gels were either stained with Coomassie brilli-
ant blue R-250 or electrotransferred onto a PVDF
membrane for the Western blot analysis. Protein spots
recognized by scFv N14 antibody were excised manually
from the Coomassie blue stained gel. The gel slices were
destained with 50% ACN/25 mM NH4HCO3,r e d u c e d
with 10 mM DTT at 56°C and alkylated in the dark
with 50 mM iodoacetamide at room temperature for
1 h. Then the gel plugs were lyophilized and immersed
in 15 μLo f1 0n g / μL trypsin solution in 25 mM
NH4HCO3. Digestion was kept at 37°C for 15 h. Tryptic
peptide mixtures were first extracted with 100 μL5 %
TFA and then with the same volume of 2.5% TFA/50%
ACN. The extracted solutions were combined, lyophi-
lized and analyzed by LC-MS. Capillary RP-HPLC of
peptide mixture was performed on a Micromass CapLC
liquid chromatography system. A fused silica tubing
Cui et al. BMC Cancer 2010, 10:356
http://www.biomedcentral.com/1471-2407/10/356
Page 3 of 14(150 mm × 75 μm i.d.) packed with PepMap C18, 3 μm
spherical particles with pore diameter 100 Å (LC Pack-
ings, Amsterdam, Netherlands) was used. The flow rate
was set at 2.5 μL/min and split into ca. 0.2 μL/min prior
to pre-column and analytical column. Mobile phase A
consisted of water/ACN (95/5, v/v) with 0.1% FA.
Mobile phase B consisted of water/TFA (5/95, v/v) with
0.1% FA. The separation was performed by running a
non-linear gradient: 4% B, in 0.1~3.5 min for injection;
4~50% B, in 3.5~63.5 min; 50~100% B, in 63.5~73.5
min. The CapLC is coupled on-line with a Q-TOF
Micro mass spectrometer (Micromass, Manchester, UK)
for detection and protein identification.
RT-PCR
Semi-quantitative reverse transcription-polymerse chain
reaction (RT-PCR) was used to determine the mRNA
transcription of hnRNP A2/B1 in primary rat hepatocytes
and rat HCC cell lines. The primers for hnRNP A2/B1
and b-actin amplification were designed according to
reference[13] with some modifications. They were F-
hnRNPA2B1 5′-TTATGGAGGAGGAAGAGGAG-3′ and
R-hnRNPA2B1 5′-CTGCATCTGCTCTGGTGTCT-3′
for hnRNP A2/B1, which give an about 450 bp RT-PCR
product. The primers for hnRNPB1 were F-hnRNPB1: 5′-
TTATGGAGGAGGAAGAGGAG-3′ and R-hnRNPB1:
5′-CTGCATCTGCTCTGGTGTCT-3′, these primers are
s p e c i f i ct oc l o n et h eg e n eo fh n R N PB 1b u tn o th n R N P
A2, and will give a 900 bp product. The primers for rat
b-actin were R-rat-actin: 5′- CTTCTCTTTAATGT-
CACGCACG-3′ and F-rat-actin: 5′-TAGCCATC-
CAGGCTGTGTTGTC-3′, which give about 230 bp
product. The total RNA was extracted respectively from
isolated rat healthy hepatocytes, cultured rat RH-35 and
CBRH 7919 HCC cells, and used for the synthesis of the
first cDNA as described in the literature (Yan-Sanders
et al [13]). The PCR 50 μl reaction mixture consisted of
0.5 μg cDNA, 0.8 μM each of the primers, 50 μMe a c ho f
dNTP and 1.5 units of Pyrobest™ DNA polymerase.
hnRNP A2/B1, hnRNP B1 and b-actin were amplified
separately with the same PCR condition. Thirty cycles
were performed as follow: 30 s at 95°C, 45 s at 55°C, and
60 s at 72°C. A final extension was performed at 72°C for
10 min. The PCR products were analyzed by electrophor-
esis on 1.2% agarose gels and visualized by ethidium bro-
mide staining. Bands were detected using a Gel Doc 2000
and intensities were quantified using Quantity One soft-
ware (Bio-Rad Laboratories). The hnRNP A2 and/or B1
transcript abundance were expressed relative to the con-
trol of b-actin.
Western blot analysis
Western blot analysis was performed using the following
antibodies: scFv N14 antibody (5 μg/ml), mouse anti-
His6 (1:3000, Amersham Bioscience) and HRP-conju-
gated goat anti-mouse IgG (1:3000, Jackson ImmunoRe-
search); or commercial polyclonal goat anti-human
hnRNP A2/B1 (1:250; Santa Cruz Biotechnology, recog-
nize both human and rat hnRNP A2/B1) and HRP-con-
jugated rabbit anti-goat IgG (1:1000, Jackson
ImmunoResearch). ß-actin (1:200; Neomarker) was used
as the control to normalize the expression levels of
hnRNP A2 and/or B1 by Quantity One software (Bio-
Rad Laboratories). For 2-D Western blot, after the iden-
tification using scFv N14 antibody, we washed the Wes-
tern blot membrane and re-probed with commercial
polyclonal goat anti-human hnRNP A2/B1 to prove that
scFv N14 antibody and commercial hnRNP A2/B1 anti-
body could recognize the same spots.
Immunofluorescence
HepG2 cells were cultured on glass cover slips, fixed for
10 minutes with 4% formaldehyde in PBS buffer, then
permeabilized with 0.5% Triton X-100 in PBS buffer for
15 minutes at room temperature. Immunofluorescence
analysis was performed using the following antibodies:
scFv N14 antibody (5 μg/ml), mouse anti-His6 (1:3000,
Amersham Bioscience) and FITC-conjugated goat anti-
mouse IgG (1:3000, Sigma). Cell nuclei were stained
with DAPI (4, 6-diamidino-2-phenylindole). After
immunostaining, the samples were observed using an
Olympus 1 × 70 fluorescence microscope.
Immunohistochemistry
Tissue sections were de-paraffinized and pre-incubated
with 0.3% H2O2 for 15 minutes. Polyclonal goat anti-
human hnRNP A2/B1 (1:250; Santa Cruz Biotechnology)
was used as the primary antibody and biotin-conjugated
rabbit anti-goat IgG as the secondary antibody. HRP-
conjugated streptavidin was used as the detection
reagent. For the negative control, the primary antibody
was replaced by PBS buffer. The sections were stained
with diaminobenzidine (DAB) and some samples were
also stained with hematoxylin. Three sections from each
sample were used for this study. The immunochemical
staining result was defined as percentage per 100 HCC
cells.
Evaluation of staining
Analyses were performed by two independent groups of
pathologists. The tissue sections were first screened at
low power (×10), and the five most representative fields
were selected. We counted 100 cells. The staining inten-
sity was semiquantitatively evaluated with a four-tiered
system: 0 (negative), 1 (weak), 2 (moderate), and 3
(strong). Weak immunoreactivity was defined as minute
granules projecting to the cell. Moderate and strong
immunoreactivity were diagnosed when a coarser and
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had weak, moderate and strong staining, then the sec-
tion was defined as positive.
Statistical analysis
Statistical analysis was performed using the SAS 9.0 sys-
tem (SAS Institute Inc.). The data of the expression
levels of hnRNP A2/B1 between normal human liver
and human hepatitis samples, normal human liver and
human HCC samples were analyzed by the Fisher’s
exact test. Wilcoxon rank sum test was used to show
the correlation between hnRNP A2/B1 distribution and
four human liver tissues (hepatitis, well-, moderately-
and poorly- differentiation).
Results and Discussion
Characterization of recombinant scFv N14 antibody
The 31 kDa recombinant scFv N14 protein was
expressed by the plasmid of pET-24a-scFv N14 in inclu-
sion bodies of E.coli BL21 (DE3) (Figure 1A). The rena-
turation of the recombinant scFv N14 successfully
yielded an active recombinant scFv N14 antibody.
The activity of recombinant scFv N14 antibody was
measured using ELISA on a typical HCC cell line
H e p G 2a n dan o r m a lc e l ll i n eL O 2a sac o n t r o l( F i g u r e
1B). The results show that the affinity of scFv N14 anti-
body to HepG2 cells is about three times higher than to
LO2 cells. This demonstrated the specificity of the
recombinant scFv N14 antibody suitable for the follow-
ing experiments. Firstly we used this antibody to detect
any antigen which could cross-react with scFv N14 anti-
body by Western blot analysis (Figure 1C). Our data
show that recombinant scFv N14 antibody can specifi-
cally recognize two bands in the whole cell lysates of
both HepG2 cells and LO2 cells. On the gel these two
protein bands are much more intense from the HepG2
cells than from LO2 cells. We then further investigated
the cellular location of the antigen by cell lysate fraction.
Cytoplasmic and nuclear proteins were fractionated
from the HepG2 cells, then separated by SDS-PAGE
and analyzed by Western blot. The results show that the
scFv N14 antibody reacts with two proteins (35 and 37
kDa) in the nuclear fraction but not in the cytoplasmic
extract (Figure 1D). This result was further confirmed
by immunofluorescent staining the cells that hnRNP
A2/B1 was mainly localized in the nuclei of HepG2 cells
(Figure 1E).
To investigate whether the scFv N14 antigen is also
up-regulated in other HCC cell lines, we chose QGY-
7701, QGY-7703 and SMMC-7721 HCC cell lines and
the non-cancerous cell line LO2 again as a control, then
analyzed the amount of scFv N14 antigen in them by
Western blot using scFv N14 antibody. Our data show
that the expression of scFv N14 antigen is increased in
the three human HCC cell lines but not in LO2 cells
and with the highest expression in the QGY-7703 HCC
c e l ll i n e( F i g u r e1 F ) .T h e r e f o r e ,w ec o n c l u d et h a tt h e
up-regulation of the scFv N14 antigen is a ubiquitous
phenomenon in HCC cells. This leads us to speculate
whether the scFv N14 antigen can be used as a new bio-
marker for human HCC research.
scFv N14 antibody is specific for hnRNP A2/B1
Our results showed that scFv N14 antigen was enriched
in the cell nucleus of HepG2 cells. In order to identity
the antigen in HepG2 cell nucleus, we ran the nuclear
protein fraction on the SDS-PAGE gel and cut the gel
into halves with the lanes of the same loadings, one half
of the gel for Western blot and the other half for stain-
ing with Coomassie brilliant blue R-250. The Western
blot detected two bands with molecular masses of
approximately 35 kDa and 37 kDa by scFv N14 antibody
(Figure 2). Gel pieces corresponding to the two protein
bands were cut out and analyzed by Q-TOF mass spec-
trometry. Each band contained three or four proteins
(Figure 2, for details in the additional files 2 and 3) but
only hnRNP A2/B1 was present in both.
We further separated the nuclear proteins using 2-D gel
electrophoresis followed by Western blot analysis. Two
spots with molecular masses of approximately 37 kDa
and 35 kDa with a pI in the range of 8.5-9.5 were iden-
tified as hnRNP A2/B1 (Figure 3, for details in the addi-
tional files 4 and 5). The Western blot membrane was
then stripped and re-probed with a polyclonal goat anti-
human hnRNP A2/B1 antibody. The result showed that
this antibody bound the same two protein spots as the
scFv N14 antibody recognized (Figure 3). Thus the
result proves that hnRNP A2/B1 is the antigen for scFv
N14 antibody. Interestingly, the antigen for scFv N14
antibody which we identified as hnRNP A2/B1 showed a
similar PI and molecular weight to the hnRNP A2/B1
identified by Lee et al in cell lysates from the human
gastric carcinoma cell line KATO III [14]. We further
used our scFv N14 antibody to blot with E. coli extract
containing the recombinant hnRNP A2 protein [21] and
as expected strong binding was observed from the Wes-
tern blot analysis (Figure 3C).
hnRNP A2/B1 is up-regulated at both transcriptional and
translational levels in proliferative rat HCC cells compared
with quiescent rat hepatocytes
We used semi-quantitative RT-PCR to analyze the tran-
scriptional level of hnRNP A2/B1 and hnRNP B1 at dif-
ferent developmental stages in the isolated healthy rat
hepatocytes and rat HCC cell lines. The normal rat
hepatocytes were isolated from the healthy liver of the
female Wistar rats, which are quiescent cells rather than
the proliferative cells. The RT-PCR results show that
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two rat HCC cell lines RH-35 and CBRH 7919 com-
pared to rat normal hepatocytes (Figure 4A) and this
was also the case for measuring only the mRNA level of
hnRNP B1 (Figure 4B), indicating that the mRNA levels
of hnRNP A2/B1 or hnRNP B1 are very low in the
quiescent stage of rat normal hepatocytes.
The translational levels of hnRNP A2 and hnRNP B1
were analyzed by Western blot respectively (Figure 4C).
The results show that hnRNP A2/B1 proteins were up-
r e g u l a t e di nt w or a tH C Cc e l ll i n e sR H - 3 5a n dC B R H
7919, but not in rat normal hepatocytes. It was noticed
that hnRNP A2 protein was more abundant than hnRNP
B1 by 3-5 fold in HepG2, QGY-7701, SMMC-7721 and
Figure 1 Characterization of scFv N14 antibody. (A) Purification of recombinant scFv N14 antibody. 1: supernatant of cell lysates of E.coli
BL21 (DE3); 2: recombinant scFv N14 antibody expressed as inclusion body; 3 and 4, purified refolding scFv N14 antibody. (B) ELISA analysis of
the binding affinity of scFv N14 antibody to LO2 and HepG2 cells. scFv N14 antibody (black bar) was incubated with LO2 and HepG2 cells, PBS
buffer (red bar) was used as the control. (C) The expression of scFv N14 antigen in HepG2 cells and LO2 cells. Equal amounts (20 μg) of whole
cell extracts from HepG2 cells or LO2 cells were loaded onto the SDS-PAGE gel and normalized by comparing with ß-actin. (D) Two protein
bands of 35 kDa and 37 kDa in the nuclear protein extract (lane N) of HepG2 cells are recognized by scFv N14 antibody. These bands are not
seen in the cytoplasmic protein extract (lane C). (E) Immunofluorescence analysis of the sub-cellular localization of scFv N14 antigen within
HepG2 cells. Cells were immunostained with scFv N14 antibody, mouse anti-His6 antibody and FITC-conjugated goat anti-mouse IgG antibodies.
DAPI was used to stain the nuclei. (F) The expression of scFv N14 antigen in human HCC cell lines QGY-7701, QGY-7703, SMMC-7721 and
human non-cancerous liver LO2 cells. Equal amounts (15 μg) of whole cell protein extracts from various cells were loaded onto the SDS-PAGE
gel and normalized by comparing with ß-actin.
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Page 6 of 14Figure 2 Identification of scFv N14 antigen. SDS-PAGE and Western blot analysis of the nuclear protein extract from HepG2 cells showing
two bands of 35 kDa and 37 kDa recognized by scFv N14 antibody (indicated by the double-arrows). Lane 1 = nuclear protein extract. Lanes 2
and 5 = nuclear protein extract incorporating a marker protein (His6-contain protein, MW = 31.0 kDa, indicated by short gray arrow). Lanes 3 and
6 = marker protein alone (long black arrow). Lane 4 = molecular weight standards. The proteins identified in both two bands (band up and
band down) were highlighted on the right.
Figure 3 Identification of scFv N14 antigen by 2D gel/Western blot/MS analysis.( A) Nuclear protein extract of HepG2 cells separated by 2-
DE, probed with scFv N14 antibody. Two protein spots reacted with scFv N14 antibody were indicated by arrows in the 2-D gel at molecular
weights of 37 kDa (spot up) and 35 kDa (spot down) and pI of around 9.0. After the identification, the Western blot membrane was stripped off
the scFv N14 antibody and re-probed with a polyclonal goat anti-hnRNP A2/B1 antibody to prove that scFv N14 and commercial hnRNP A2/B1
could detect the same spots. (B) Peptide sequences identified from spot down by Q-TOF analysis. (C) Western blot showing scFv N14 bound
with recombinant hnRNP A2. Various amounts of hnRNP A2 (Lane 1, 0.4 μg; Lane 2, 0.7 μg; Lane 3, 1.4 μg) were mixed with 20 μg the extracts
of E.coli Top10 (Invitrogen) and loaded onto the SDS-PAGE gel. ScFv N14 antibody can specifically recognize recombinant hnRNP A2 protein.
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Page 7 of 14Figure 4 The over-expression of hnRNP A2/B1 and hnRNP B1 in the mRNA and protein levels in HCC cell lines. (A) The mRNA
expression of hnRNP A2/B1 in rat hepatocytes and rat HCC cell lines RH-35 and CBRH-7919. hnRNP A2/B1 mRNA product (450 bp) and b-actin
mRNA product (230 bp) are shown in the figure. The blot presents two groups of total 6 independent RT-PCR experiments. The value in the
graph is presented as mean ± standard deviation. (B) The mRNA expression of hnRNP B1 in rat hepatocytes and rat HCC cell lines RH-35 and
CBRH-7919. hnRNP B1 mRNA product (900 bp) and b-actin mRNA product (230 bp) are shown in the figure. The blot presents two groups of
total 6 independent RT-PCR experiments. The value in the graph is presented as mean ± standard deviation. (C) The protein expression of
hnRNP A2/B1 in rat hepatocytes and two rat HCC cell lines. Equal amounts (15 μg) of whole cell protein extracts from rat hepatocytes, rat HCC
cell RH-35 and rat HCC cell CBRH-7919 were loaded onto the SDS-PAGE gel and normalized by comparing with ß-actin. Western blot detected
two protein bands of 35 kDa (hnRNP A2) and 37 kDa (hnRNP B1) in the whole cell extracts of rat HCC cell lines RH-35 and CBRH-7919. Western
blot result is a representative of three independent experiments.
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Page 8 of 14RH-35 HCC cell lines, but that these two isoforms were
equally expressed in HCC cell lines of QGY-7703 and
CBRH-7919 (Figure 1F and 4C). Further investigation is
required to explain this result.
hnRNP A2 is involved in cell proliferation [22]. Redu-
cing hnRNP A2 expression in Colo16 and HaCaT cells
by RNAi led to a non-apoptotic-related decrease in cell
proliferation [22]. David et al [23] demonstrated that
human gliomas overexpressed c-Myc, PTB (polypyrimi-
dine tract binding protein), hnRNP A1 and hnRNP A2
to regulate the overexpression of PKM2 (pyruvate kinase
isoform 2), which is universally re-expressed in cancer
and promotes oxidative aerobic glycolysis [24]. Further-
more, aerobic glycolysis [25] is known to be important
for cell growth and tightly regulated in a proliferation-
linked manner [26,27]. In this study, we found that
hnRNP A2/B1 expression at transcriptional and transla-
tional level was up-regulated in the proliferative HCC
cells rather than in the quiescent hepatocytes, and this
agrees with the fact that the overexpression of hnRNP
A2/B1 is required for cell proliferation.
hnRNP A2/B1 expression is up-regulated in human
hepatitis and hepatocellular carcinoma tissue samples
An immuno-histochemical approach was used to mea-
sure the expression levels of hnRNP A2/B1 in 70 various
human live tissues, including healthy liver tissues. The
sample information is listed in Table S1 (additional file
1) and the hnRNP A2/B1 expression level is shown in
Table 1 and 2. We counted 100 cells in each section
and classified the sections into two groups: tissue sam-
ples with less than 5% of cells stained were classified as
negative; those with 5% or more staining were classified
as positive. All of the 6 normal liver tissue samples were
negative for hnRNP A2/B1 expression (Figure 5A). In
contrast, all 10 hepatitis tissue samples were positive for
hnRNP A2/B1 expression (Figure 5B). The 54 HCC tis-
sue samples showed various staining levels for the
amount of hnRNP A2/B1 immunoreacted with its speci-
f i ca n t i b o d y( F i g u r e5 C - F )a n dt h e r ei sn o n eo ro n l y
marginal staining observed in the peritumoral cirrhotic
area of the HCC tissues (data not shown). In all 10
hepatitis tissue samples, we observed the regularity of
the granule distribution throughout the whole nucleus
without any relation with their pathological stage. How-
ever, in the human HCC tissues, the positive immuno-
chemical staining was more intense compared to that of
the hepatitis tissues. In general the coarse and thickened
granules were mainly dispersed throughout the nucleus,
or cytoplasm in cancerous hepatocytes (Figure 5).
5 out of 54 HCC tissue samples showed a very low
detectable hnRNP A2/B1 expression and were consid-
ered as negative, while the remaining 49 were all posi-
tive. Statistical analyses show a significant differences of
the expression levels of hnRNP A2/B1 between normal
human liver tissues and human hepatitis tissues
(Table 1, Fisher test, P < 0.01), and between normal
human liver tissues and human HCC tissues (Table 1,
Fisher test, P < 0.01). These immunohistochemistry
results show that hnRNP A2/B1 is expressed highly in
both hepatitis-positive and HCC liver tissues but not in
normal human liver tissues, which is consistent with our
results obtained in rat by molecular biochemical
approaches (Figure 4).
In our study, we observed that the hnRNP A2/B1 was
over-expressed in the cell nuclei of human hepatitis
samples. hnRNP A2/B1 was also reported as being over-
expressed in both histologically normal and abnormal
bronchial epithelial cells from chronic smokers [28].
Hepatitis virus infection and chronic smoking are
known factors for the carcinogenesis of human liver
cancer and lung cancer respectively [28,29]. In the case
of hepatitis virus infection of the liver, continuous
Table 2 hnRNP A2/B1 subcellular localization in HCC
tissues with different histopathological grades by
immunohistochemistry
hnRNP A2/B1
distribution
Hepatitis HCC
Well Moderately Poorly
N1 0
(100%)
5
(42%)
5 (22%) 2 (14%)
N+C 0 6
(50%)
9 (39%) 2 (14%)
C 0 1 (8%) 9 (39%) 10
(72%)
Total 10 12 23 14
1: Subcellular localization is described as N, nuclear localization; N+C, both
nuclear localization and cytoplasmic localization observed in the same sample;
C, cytoplasmic localization;
2: Three groups of HCC tissues were defined as Well-differentiation,
Moderately-differentiation, Poorly-differentiation according to the degree of
tumor differentiation;
3: P value of the correlation between hnRNP A2/B1 subcellular localization
and the degree of HCC tumor differentiation, P = 0.0001, P < 0.05 (Wilcoxon
rank sum test, statistical analysis see additional file 6).
Table 1 hnRNP A2/B1 expression status in normal human
liver versus human hepatitis tissues, and normal
human liver versus human HCC tissues by
immunohistochemistry
hnRNP A2/B1 expression status Normal Hepatitis HCC
Negative 6 0 5
Positive 0 10 49
Total 6 10 54
1: P value of hnRNP A2/B1 expression status between normal human liver
samples and human hepatitis samples was <0.01 (Fisher test, statistical
analysis see additional file 6). Human hepatitis sample is viral related hepatitis.
2: P value of hnRNP A2/B1 expression status between normal human liver
samples and human HCC samples was <0.01 (Fisher test, statistical analysis
see additional file 6).
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Page 9 of 14inflammation and oxidative stress facilitates the accumu-
lation of genetic alterations within the hepatocytes [29].
hnRNP A2/B1 was indeed found to be involved in the
process of DNA repair. Freshly cultured human kerati-
nocytes were irradiated of 100 J/m
2 medium wavelength
( U V - B ) ,a f t e r6h ,m i c r o a r r a ya n a l y s i ss h o w e dt h a t
hnRNP B1 mRNA transcript was increased 2.8 fold
compared with the control [30]. Whereas, Iwanaga et al
[31] showed that hnRNP B1 over-expression results in
the accumulation of DNA repair errors by inhibiting
DNA-dependent protein kinase (DNA-PK) activity. Man
et al [17] reported that in pulmonary tissue samples
hnRNP A2/B1 positive cells contained a significantly
higher frequency of microsatellite alteration (MA) and
loss of heterozygosity (LOH) compared with cells with
no detectable hnRNP A2/B1. Although the mechanisms
of hepatocarcinogenesis are still not completely under-
stood, the development and progression of HCC is
believed to be the result of accumulated genetic
changes. The observation that hnRNP A2/B1 is over-
expressed in human hepatitis tissues indicates that
hnRNP A2/B1 is involved in the promotion of the
hepatocarcinogenesis.
hnRNP A2/B1 has been suggested to be an onco-
developmental protein, it was found that within the
developing human lung (from 20 weeks onward),
hnRNP A2/B1 had the highest expression level in the
epithelial cells. However, these levels were reduced in
Figure 5 Immunostaining of hnRNP A2/B1 in human liver tissue samples. Tissue samples were incubated with a commercial goat
polyclonal anti-human hnRNP A2/B1 specific antibody and visualized using diaminobenzidine. (A) Human normal liver tissue showing negative
staining (×20). (B) Hepatitis tissue sample showing positive staining of the hepatocyte nuclei (Marked N) (×20). (C) HCC tissue sample showing a
nuclear staining pattern (Marked N) (×20). (D) HCC tissue sample showing both cytoplasmic (Marked C) (long arrow) and nuclear staining
(Marked N) (short arrow) within discrete cell clusters (×20). (E) HCC tissue sample showing cytoplasmic staining patterns (Marked C) (×20). (F)
HCC tissue sample showing a cytoplasmic staining pattern. The cell nuclei have been counterstained with hematoxylin (Marked C) (×10).
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Page 10 of 14the adult lung [18]. hnRNP A2/B1 is required for cell
proliferation [18,24] and contributes to the uncontrolled
cell division that is typically seen in cancers [32].
Furthermore, many of its downstream targets are
involved in the regulation of the cell cycle and cell pro-
liferation [33]. Other studies showed that small RNA
interference targeting of hnRNP A1 and A2 induces cell
death in cancer cell lines but not in normal cell lines
[34]. Moreover, hnRNP A2/B1 was found to play a role
in tumor invasion. Tumorigenic Hep3B cells expressed
higher levels of hnRNP A2/B1 than non-tumorigenic
HepG2 cells [35]. hnRNP A2 is important in generating
appropriate of the Golgi complex, which is required for
polarized cell migration and for tumor cell invasion
[36,37]. The study of Guha et al also suggests that
hnRNP A2 is very important in the induction of cell
growth and invasiveness stimulated by mitochondrial
stress [38,39]. Taking together with our results, we sug-
gest that hnRNP A2/B1 is also required for the prolif-
eration and tumor invasion of HCC.
Cytoplasmic localization of hnRNP A2/B1 is an indicator
of the dedifferentiation of hepatocellular carcinoma
hnRNP A2/B1 is various subcellularly localized in
human hepatitis and HCC tissues. We defined 3 pat-
terns of hnRNP A2/B1 subcellular localization. The
sample sections with all the cell clusters of nuclear
staining were defined as nuclear localization (N) (Figure
5B and 5C); the sections with all the cell clusters of
cytoplasmic staining were defined as cytoplasmic locali-
zation (C) (Figure 5E and 5F); the sections with both
nuclear and cytoplasmic staining observed simulta-
neously in discrete clusters of cancerous cells within the
same sample were defined as both nuclear and cytoplas-
mic localization (N+C), they contain at least one cluster
of cells of nuclear or cytoplasmic staining (Figure 5D).
In 10 positive hnRNP A2/B1 staining hepatitis tissue
samples (Table 2), hnRNP A2/B1 was exclusively
expressed in the cell nuclei (Figure 5B). Whereas, in 49
HCC positive staining tissue samples all three patterns
of hnRNP A2/B1 subcellular localization were observed.
According to the developmental stages, 49 immuno-
chemical staining positive human HCC samples were
classified into 3 groups: 12 well-differentiated HCC sam-
ples, 23 moderately-differentiated and 14 poorly-differ-
entiated (Figure 6 and Table 2). In 12 well-differentiated
HCC tissue samples, 8% of them showed hnRNP A2/B1
cytoplasmic localization, 42% nuclear localization and
50% showed both cytoplasmic and nuclear localiztion
within discrete cell clusters in the same tissue sample.
In 23 moderately-differentiated samples, the percentage
of cytoplasmic localized samples increased to 39% while
the percentage of nuclear localization, both nuclear and
cytoplasmic localization samples decreased to 22% and
39% respectively. Interestingly, in 14 poorly-differen-
tiated HCC samples, 72% of them had cells with hnRNP
A2/B1 localized in cytoplasm and 14% in nuclear and
the same percentage in both cytoplasmic and nuclear
localization (Table 2). Therefore, the above results show
a clear increasing trend in the percentage of hnRNP A2/
B1 cytoplasmic localization tissue samples from well-dif-
ferentiated to poorly-differentiated stages (Figure 6).
The results of Wilcoxon rank sum test show a signifi-
cant correlation (P = 0.0001, P < 0.05) between the sub-
cellular localization of hnRNP A2/B1 and the different
stages of human liver tissues (Table 2). These results
suggested that the cell localization of hnRNP A2/B1
from the nucleus to the cytoplasm in the hepatocytes is
correlated to HCC development.
During the dedifferentiation of the tumor cells, the
malignant potential increases, as reflected in intrahepatic
metastasis and vascular invasion. This transformation
occurs non-uniformly within a given tumor nodule,
resulting in the coexistence of well-differentiated and
moderately- to poorly- differentiated lesions within the
same nodule. This has been termed by histologists a
‘nodule-in-nodule’ or ‘mosaic’ appearance [40]. This
might explain the diversity of the hnRNP A2/B1 subcel-
lular localization in human HCC tissues observed in this
study.
Figure 6 The subcellular localization of hnRNP A2/B1 in human
hepatitis and HCC tissues. The number of samples defined as
nuclear localization (red bar), both nuclear and cytoplasmic localization
(white bar) and cytoplasmic localization (black bar) in each group of
human liver tissues (viral hepatitis, well differentiation HCC, moderately
differentiation HCC and poorly differentiation HCC) was expressed as
percentage respectively (Data obtained from Table 2).
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Page 11 of 14Nuclear localization of hnRNP A2/B1 in cultured
cell lines is known. However, the stimulation by acti-
nomycin D or adenosine dialdehyde will cause the
nuclei-cytoplasm translocation of hnRNP A2/B1
[16,41]. Several studies described some possible
mechanisms involved in the up-regulation and subcel-
lular translocation of hnRNP A2/B1. Kit Wan et al
[42] reported that over-expression of EGFP-SUMO-1
(sumoylation-1) will increase the expression of hnRNP
B1 in HepG2 cells. Pioli et al [43] presented that
hnRNP A2 interacts with an ubiquitin-protein isopep-
tide ligase, pVHL. The post-translational modification
of hnRNP A2/B1 might protect the proteins from
degradation resulting in the observed high protein
expression and subcelluar translocation. Nichols et al
showed that the translocation of hnRNP A2 to cyto-
plasm was linked to the pattern of methylation within
the RGG domain (R191-G253) by inhibiting the
methyltransferase enzyme [16,44], while the research
of Bosser et al also suggested that the phosphorylation
might be another mechanism affects the cellular loca-
lization of hnRNP A2 [45].
Man et al speculated that subcellular localization of
hnRNP A2/B1 might be an important factor associated
with tumor progression. They reported that in lung can-
cer tissues, cells with hnRNP A2/B1 presented in the
cytoplasm had a 3-fold higher frequency of MA and
LOH than cells with hnRNP A2/B1 confined to the
nucleus [17]. Nichols et al assumed that the cytoplasmic
over-expression of hnRNP A2 in airway epithelial cells
was associated with neoplastic transformation and/or
tumorigenesis [16]. Interestingly, the various subcellular
localizations of hnRNP A2/B1 in human cancer tissues
were observed in many cases, however, the isoform
hnRNP B1 is up to now reported exclusively to be loca-
lized in the nucleus [32,46-49]. Therefore, we speculate
that in the poorly-differentiated HCC tissues only the
isoform of hnRNP A2 is very likely over-expressed in
the cell cytoplasm. hnRNP A2 and hnRNP B1 are two
closely related splice variants of the hnRNP A/B family
[5], hnRNP A2/B1 are often functionally studied
together. There are reported antibodies that recognize
hnRNP A2/B1 [10] or hnRNP B1 respectively [41]. In
this study, our scFv N14 antibody and commercial
hnRNP A2/B1 antibody both exhibited relative limita-
tion considering that they can not distinguish hnRNP
B1 from hnRNP A2/B1. It is worthwhile in the future to
distinguish the subcellular localization of these two iso-
forms by using their specific antibodies in immunohisto-
chemical experiments.
Conclusions
hnRNP A2/B1 was identified as the antigen of the scFv
N14 antibody, which specifically recognizes HepG2
HCC cells but not human non-cancerous liver LO2
cells. hnRNP A2/B1 was observed highly expressed at
both transcriptional and translational levels in cultured
rat HCC cell lines but not in rat hepatocytes. hnRNP
A2/B1 has low expression in human normal tissues,
but is over-expressed in human hepatitis and HCC tis-
sues. The high expression of hnRNP A2/B1 might pro-
mote the hepatocarcinogenesis in these hepatitis
patients, and the increased expression of hnRNP A2/
B1 is assumed to be required for cell proliferation and
tumor invasion. Another interesting phenomena
revealed in this study is that, in human hepatitis tis-
sues, hnRNP A2/B1 is exclusively distributed in the
nucleus; in most of the well differentiated human HCC
tissues, hnRNP A2/B1 mainly accumulates in the
nucleus; while in most of the poorly differentiated
human HCC tissues, it is predominantly localized in
the cytoplasm. The increased cytoplasmic localization
of hnRNP A2/B1 is correlated to the progression in
de-differentiation of hepatocytes. Considering the com-
plexity of human HCC, we believe that the detection
of cytoplasmic over-expression of hnRNP A2/B1 is a
very promising diagnostic biomarker to use for HCC
risk stratification and treatment monitoring.
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